Cardiometabolic Biomarkers at Age 44-45 in the Psychosis Spectrum: The British National Child Development Study
Schizophrenia Bulletin · 10.04.2026 · 52 (3)
DOI: 10.1093/schbul/sbag040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Schizophrenia Bulletin, online erschienen am 05.05.2026. Verfasst von Eugenia Kravariti und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, United Kingdom. Hauptthemen laut MEDLINE: Psychotic Disorders, Cardiovascular Diseases, Adverse Childhood Experiences. Die Arbeit nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Economic and Social Research Council, ESRC Centre for Society and Mental Health at King's College London, Erasmus+ programme.
Abstract (Originalsprache)
Background
Excess mortality in psychotic disorders is largely due to preventable cardiometabolic morbidity. Efforts to evaluate the link between the psychosis spectrum and cardiometabolic health have been confounded by early-life adversity (ELA) and biased sampling. This population-based study examined prospective associations between psychosis-spectrum status and cardiometabolic biomarkers at age 44-45, adjusting for ELA. Study Design We analyzed data from the 2002/03 biomedical sweep of the British National Child Development Study (n = 9377; age 44-45). Psychosis-spectrum status (exposure; n = 171) was defined using repeated screening across adulthood (ages 23 to 44-45), including self-reported diagnoses, antipsychotic medication use, or professional help-seeking for hallucinations. Cardiometabolic biomarkers at age 44-45 (outcomes) were compared between individuals on the psychosis spectrum and psychosis-free controls (comparator; n = 2448). Analyses were conducted using unimputed and multiply imputed datasets (n = 7391-9298), adjusting for 24 indicators of ELA. Study Results In both unimputed/imputed analyses, individuals on the psychosis spectrum had significantly worse cardiometabolic profiles. Adjusted results showed elevated abdominal obesity (exp(b), 1.404; 95% CI, 1.177-1.676; P < .001), higher glycated hemoglobin (B = 0.321; 95% CI, 0.089-0.553; P = .008), lower high-density lipoprotein cholesterol (B = –4.472; 95% CI, –7.782 to –1.162; P = .009), and increased fibrinogen (B = 4.542; 95% CI, 0.939-8.144; P = .015) compared to controls.
Conclusions
Overcoming early-life confounders and biases that limited prior research, our study demonstrates a robust, independent association between psychosis-spectrum status and cardiometabolic dysfunction at age 44-45. These findings underscore the urgent need for comprehensive screening, treatment, and monitoring of cardiometabolic morbidity in psychosis, guided by a life-course perspective.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Psychosis Studies, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London SE5 8AF, United Kingdom.
- Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029, United States.
- First Department of Psychiatry, School of Medicine, National and Kapodistrian University of Athens, Athens 115 28, Greece.
- Centre for Longitudinal Studies, Social Research Institute, University College London, London WC1H 0AL, United Kingdom.
Förderung
- Economic and Social Research Council
- ESRC Centre for Society and Mental Health at King's College London
- Erasmus+ programme
- NIMH NIH HHS
- ESRC Centre for Society and Mental Health at King’s College London
- National Institute of Mental Health
Zitieren
APA
Kravariti, E., Reichenberg, A., Fragkaki, A. M., Murray, R. M., & Ploubidis, G. B. (2026). Cardiometabolic Biomarkers at Age 44-45 in the Psychosis Spectrum: The British National Child Development Study. Schizophrenia Bulletin, 52(3). https://doi.org/10.1093/schbul/sbag040
Vancouver
Kravariti E, Reichenberg A, Fragkaki AM, Murray RM, Ploubidis GB. Cardiometabolic Biomarkers at Age 44-45 in the Psychosis Spectrum: The British National Child Development Study. Schizophrenia Bulletin. 2026;52(3). doi:10.1093/schbul/sbag040
BibTeX
@article{Kravariti2026,
author = {Kravariti, Eugenia and Reichenberg, Abraham and Fragkaki, Anna Maria and Murray, Robin M and Ploubidis, George B},
title = {Cardiometabolic Biomarkers at Age 44-45 in the Psychosis Spectrum: The British National Child Development Study},
journal = {Schizophrenia Bulletin},
year = {2026},
volume = {52},
number = {3},
doi = {10.1093/schbul/sbag040}
}
EUVIMED